Here are Monday's biggest analyst calls: Nvidia, SpaceX, Tesla, Apple, Netflix, Deckers, Biogen, Nio & more

Wall Street issued a broadly positive slate of calls: Jefferies raised Tesla’s Q2 EBIT to $1.45B and lifted its price target to $400 (from $375), while JPMorgan upgraded American Express to overweight and framed its affluent customer base as relatively shielded from the Middle East/energy squeeze. Several additional upgrades/initiations (e.g., Shopify to buy, Nvidia reiterated outperforming, and multiple biotech and energy/service names to overweight/buy) are centered on earnings durability, AI positioning, and pipeline value, with Apple being the main counterweight via a lowered Netflix-like ad-monetanization concern. Net impact is likely more supportive for individual stocks than the broader market, given this is primarily analyst rating/price-target action.

Analysis

This tape is less a broad risk-on signal than a rotation into scarce growth with defensive earnings variance. The cleanest second-order beneficiary is KEYS: AI network buildout expands the test/validation layer even if headline GPU spend normalizes, so it can keep compounding on capex breadth rather than unit volume alone. AXP is the other high-quality expression: affluent interchange and lending tend to hold up better than the mass-market card complex when energy/fuel pressure bites, and that mix can widen share gains versus lower-income issuers.

The utility calls on ATO and MDU matter because datacenter load is turning regulated wires into a growth asset class, not just a bond proxy. That creates a 6-18 month re-rating path if ROE approvals and interconnect demand keep trending up, but the trade breaks if rates back up sharply or if datacenter commitments slip. On the consumer side, DIS/NFLX/SHOP/TSLA look crowded as analyst-led mean reversion stories; the market will need actual earnings revision support, not just lower expectations, to sustain upside.

Contrarian view: the market may be over-interpreting a cluster of upgrades as a macro signal when much of it is idiosyncratic and late-cycle. Biotech is especially binary here — BIIB, PRAX, STOK, ONC, EQ, KARD, BTSG are catalyst names, not basket longs. If the next earnings season fails to confirm these revisions, the post-open pop is likely to fade faster than usual.

Key Decisions for Investors

• Long KEYS on any post-gap retracement; 1-3 month hold into AI networking spend updates. Risk/reward is attractive if order growth confirms broader AI capex, but exit if hyperscaler capex commentary rolls over.
• Pair trade: long AXP / short BBY for a 1-3 month consumer-split expression. AXP benefits from affluent spending resilience; BBY is more exposed to pressured discretionary budgets and margin compression if fuel remains sticky.
• Initiate a small long in ATO or MDU as a 6-12 month regulated-growth/AI-power-load play. Use rate spikes or weak utility tape to add; thesis fails if datacenter load disappoints or the 10Y backs up materially.
• Treat SAIA as a tactical cyclical alert, not a chase buy: go long only if freight data and yields keep improving over the next 4-6 weeks. If volumes or pricing flatten, the upside from the upgrade is likely exhausted.
• Avoid a biotech basket here; trade BIIB/PRAX/STOK only around event dates with tight sizing. The base-rate risk is binary disappointment, and analyst targets do not offset readout volatility.